Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes (Q38642435)

5 September 2017

Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes (English)

1 reference

5 September 2017

0 references

1 reference

1 reference

Fida Bacha

1

1 reference

PubMed ID

26592507

5 September 2017

Sara Klinepeter Bartz

series ordinal

2

1 reference

5 September 2017

23 November 2015

1 reference

5 September 2017

1 reference

5 September 2017

17

1 reference

5 September 2017

8

1 reference

5 September 2017

545-558

1 reference

Type I diabetes mellitus. A chronic autoimmune disease

5 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Incidence of childhood obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Changing Prevalence of Overweight Children and Adolescents at Onset of Insulin-Treated Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Overweight and Obesity Based on Four Reference Systems in 18,382 Paediatric Patients with Type 1 Diabetes from Germany and Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The T1D Exchange clinic registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin resistance in children: consensus, perspective, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Potential adjunctive therapies in adolescents with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin sensitivity in Type 1 diabetic children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Impact of physical fitness and glycemic control on in vivo insulin action in adolescents with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Can clinical factors estimate insulin resistance in type 1 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Body mass index at the time of diagnosis of autoimmune type 1 diabetes in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Plateau of adiposity in Australian children diagnosed with Type 1 diabetes: a 20-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Predictors of increasing BMI during the course of diabetes in children and adolescents with type 1 diabetes: data from the German/Austrian DPV multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Serum adiposity-induced biomarkers in obese and lean children with recently diagnosed autoimmune type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

A comparison of multiple daily insulin therapy with continuous subcutaneous insulin infusion therapy in adolescents with type 1 diabetes mellitus: a single-center experience from Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin resistance during puberty: results from clamp studies in 357 children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Continuous rise of insulin resistance before and after the onset of puberty in children at increased risk for type 1 diabetes - a cross-sectional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Growth, growth factors and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Diastolic function is reduced in adolescents with type 1 diabetes in response to exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Potential role of non-insulin adjunct therapy in Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Insulin analogues in children and teens with type 1 diabetes: advantages and caveats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The target of metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The mode of action of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Pharmacologic treatment of type 2 diabetes: oral medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The effect of rosiglitazone on overweight subjects with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Pharmacologic treatment of type 2 diabetes: injectable medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The potential of incretin-based therapies in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Regulation of glucagon secretion by incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The role of adjunctive exenatide therapy in pediatric type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Possible adverse effects of SGLT2 inhibitors on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

SGLT2 Inhibitors May Predispose to Ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Increased Overnight Growth Hormone Concentrations in Diabetic Compared with Normal Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: Assessment by the artificial pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPEDI.12337

21 January 2018

Identifiers

DOI

10.1111/PEDI.12337

1 reference

5 September 2017

1 reference

PubMed ID

26592507